Replies to post #8511 on Cytodyn Inc (CYDY)

[Saltz]

Primary endpoint is only one week after full enrollment.

[Saltz]

P3 Mono quick but not going to fully enroll 300 patients in 2016. Adjunct P3 not quick but only 30 patients. What I heard Nader say is full enrollment and primary endpoint as early as Q1 2017 for Adjunct. He lumps enrollment and primary endpoint together because primary endpoint is one week after enrollment is completed.

[Saltz]

I agree on the importance of hitting timelines. IMO make good on full enrollment on both P3's by end of Q1 2017 - the data will determine Pro-140s destiny and value by the end of 2017.

Getting further bogged down on either P3 with delays will be a huge red flag as to Nader's competency. This is a make it or break it year for this company. Cannot afford to raise $'s with an eroding SP.